FDA approves Roche and Eli Lilly Alzheimer's blood diagnostic test

The U.S. FDA has granted approval for a blood-based diagnostic test for Alzheimer's disease developed by Roche and Eli Lilly. This approval marks a significant shift toward less invasive, scalable screening methods for neurodegenerative conditions, though the clinical adoption rate and insurance reimbursement landscape remain to be determined.